New Pulmonary Hypertension Model in Conscious Dogs to Investigate Pulmonary-selectivity of Acute Pharmacological Interventions

Overview

Journal Eur J Appl Physiol

Specialty Physiology

Date 2017 Nov 22

PMID 29159668

Citations 4

Authors

Thomas Mondritzki

Philip Boehme

Lena Schramm

Julia Vogel

Ilka Mathar

Peter Ellinghaus

Peter Kolkhof

Erwin Bischoff

Jorg Huser

Wilfried Dinh

Peter Sandner

Hubert Truebel

Affiliations

Soon will be listed here.

Abstract

Purpose: Testing of investigational drugs in animal models is a critical step in drug development. Current models of pulmonary hypertension (PH) have limitations. The most relevant outcome parameters such as pulmonary artery pressure (PAP) are measured invasively which requires anesthesia of the animal. We developed a new canine PH model in which pulmonary vasodilators can be characterized in conscious dogs and lung selectivity can be assessed non-invasively.

Methods: Telemetry devices were implanted to measure relevant hemodynamic parameters in conscious dogs. A hypoxic chamber was constructed in which the animals were placed in a conscious state. By reducing the inspired oxygen fraction (FiO) to 10%, a hypoxic pulmonary vasoconstriction was induced leading to PH. The PDE-5 inhibitor sildenafil, the current standard of care was compared to atrial natriuretic peptide (ANP).

Results: The new hypoxic chamber provided a stable hypoxic atmosphere during all experiments. The mean PAP under normoxic conditions was 15.8 ± 1.8 mmHg. Hypoxia caused a reliable increase in mean PAP (+ 12.2 ± 3.2 mmHg, p < 0.0001). Both, sildenafil (- 6.8 ± 4.4 mmHg) and ANP (- 6.4 ± 3.8 mmHg) significantly (p < 0.05) decreased PAP. Furthermore sildenafil and ANP showed similar effects on systemic hemodynamics. In subsequent studies, the in vitro effects and gene expression pattern of the two pathways were exemplified.

Conclusions: By combining the hypoxic environment with the telemetric approach, we could successfully establish a new acute PH model. Sildenafil and ANP demonstrated equal effects regarding pulmonary selectivity. This non-invasive model could help to rapidly screen pulmonary vasodilators with decreased animal burden.

Citing Articles

The Role of Personalized Medicine in Companion Animal Cardiology.

Rivas V, Stern J, Ueda Y Vet Clin North Am Small Anim Pract. 2023; 53(6):1255-1276.

PMID: 37423841 PMC: 11184409. DOI: 10.1016/j.cvsm.2023.05.016.

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

Becker-Pelster E, Hahn M, Delbeck M, Dietz L, Huser J, Kopf J Respir Res. 2022; 23(1):272.

PMID: 36183104 PMC: 9526466. DOI: 10.1186/s12931-022-02189-1.

Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension.

Akabane R, Sato T, Sakatani A, Ogawa M, Nagakawa M, Miyakawa H J Vet Med Sci. 2020; 82(4):446-451.

PMID: 32101822 PMC: 7192714. DOI: 10.1292/jvms.19-0595.

Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension.

Ueda Y, Johnson L, Ontiveros E, Visser L, Gunther-Harrington C, Stern J Sci Rep. 2019; 9(1):6899.

PMID: 31053768 PMC: 6499771. DOI: 10.1038/s41598-019-43318-z.

References

Lara-Pezzi E, Menasche P, Trouvin J, Badimon L, Ioannidis J, Wu J . Guidelines for translational research in heart failure. J Cardiovasc Transl Res. 2015; 8(1):3-22. DOI: 10.1007/s12265-015-9606-8. View

McKie P, Ichiki T, Burnett Jr J . M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2011; 14(1):62-9. DOI: 10.1007/s11906-011-0244-5. View

Saito Y . Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol. 2010; 56(3):262-70. DOI: 10.1016/j.jjcc.2010.08.001. View

Hohne C, Drzimalla M, Krebs M, Boemke W, Kaczmarczyk G . Atrial natriuretic peptide ameliorates hypoxic pulmonary vasoconstriction without influencing systemic circulation. J Physiol Pharmacol. 2004; 54(4):497-510. View

Liu L, Cheng H, Chin W, Jin H, Oparil S . Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease. Am J Med Sci. 1989; 298(6):397-401. DOI: 10.1097/00000441-198912000-00007. View

Anker S, Ponikowski P, Mitrovic V, Peacock W, Filippatos G . Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015; 36(12):715-23. PMC: 4368857. DOI: 10.1093/eurheartj/ehu484. View

Zakeri R, Burnett J . Designer natriuretic peptides: a vision for the future of heart failure therapeutics. Can J Physiol Pharmacol. 2011; 89(8):593-601. DOI: 10.1139/y11-048. View

Handoko M, Schalij I, Kramer K, Sebkhi A, Postmus P, van der Laarse W . A refined radio-telemetry technique to monitor right ventricle or pulmonary artery pressures in rats: a useful tool in pulmonary hypertension research. Pflugers Arch. 2007; 455(5):951-9. PMC: 2137943. DOI: 10.1007/s00424-007-0334-z. View

Preston I, Hill N, Gambardella L, Warburton R, Klinger J . Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood). 2004; 229(9):920-5. DOI: 10.1177/153537020422900908. View

10.

McLaughlin V, Archer S, Badesch D, Barst R, Farber H, Lindner J . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American.... J Am Coll Cardiol. 2009; 53(17):1573-619. DOI: 10.1016/j.jacc.2009.01.004. View

11.

Lawrie A . A report on the use of animal models and phenotyping methods in pulmonary hypertension research. Pulm Circ. 2014; 4(1):2-9. PMC: 4070757. DOI: 10.1086/674886. View

12.

Ghofrani H, Galie N, Grimminger F, Grunig E, Humbert M, Jing Z . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330-40. DOI: 10.1056/NEJMoa1209655. View

13.

de Bold M, Sheffield W, Martinuk A, Bhakta V, Eltringham-Smith L, de Bold A . Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris. Regul Pept. 2012; 175(1-3):7-10. DOI: 10.1016/j.regpep.2012.01.005. View

14.

Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H . Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res. 2009; 82(1):30-9. DOI: 10.1093/cvr/cvp002. View

15.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016; 69(2):177. DOI: 10.1016/j.rec.2016.01.002. View

16.

Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S . Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during.... J Am Coll Cardiol. 2010; 55(17):1844-51. DOI: 10.1016/j.jacc.2009.11.085. View

17.

Goodchild C, Serrao J . Cardiovascular effects of propofol in the anaesthetized dog. Br J Anaesth. 1989; 63(1):87-92. DOI: 10.1093/bja/63.1.87. View

18.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Respir J. 2015; 46(4):903-75. DOI: 10.1183/13993003.01032-2015. View

19.

Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M . Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009; 53(12):1040-6. DOI: 10.1016/j.jacc.2008.10.061. View

20.

Jin H, Yang R, Thornton R, Chen Y, Jackson R, Oparil S . Atrial natriuretic peptide lowers pulmonary arterial pressure in hypoxia-adapted rats. J Appl Physiol (1985). 1988; 65(4):1729-35. DOI: 10.1152/jappl.1988.65.4.1729. View